Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kasper Recourt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Genes|August 26, 2022
FHH Quick App Review: How Can a Quality Review Process Assist Primary Care Providers in Choosing a Family Health History App for Patient Care?Grant M Wood, Sander van Boom, Kasper Recourt, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2023
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating ScaleMarije E Otto, Kirsten R Bergmann, Marieke L de Kam, et al.
Frontiers in Neuroscience|February 18, 2025
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depressionKasper Recourt, Joop Van Gerven, Nadieh Drenth, et al.
Translational Psychiatry|October 4, 2019
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorderKasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry|September 5, 2019
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorderKasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry|July 23, 2023
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorderKasper Recourt, Peter de Boer, Peter van der Ark, et al.
Journal of Psychopharmacology (Oxford, England)|April 7, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trialKasper Recourt, Jasper van der Aart, Gabriel Jacobs, et al.
Frontiers in Psychiatry|May 24, 2021
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar DepressionOleksandr Sverdlov, Jelena Curcic, Kristin Hannesdottir, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Genes|August 26, 2022
FHH Quick App Review: How Can a Quality Review Process Assist Primary Care Providers in Choosing a Family Health History App for Patient Care?Grant M Wood, Sander van Boom, Kasper Recourt, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2023
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating ScaleMarije E Otto, Kirsten R Bergmann, Marieke L de Kam, et al.
Frontiers in Neuroscience|February 18, 2025
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depressionKasper Recourt, Joop Van Gerven, Nadieh Drenth, et al.
Translational Psychiatry|October 4, 2019
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorderKasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry|September 5, 2019
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorderKasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry|July 23, 2023
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorderKasper Recourt, Peter de Boer, Peter van der Ark, et al.
Journal of Psychopharmacology (Oxford, England)|April 7, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trialKasper Recourt, Jasper van der Aart, Gabriel Jacobs, et al.
Frontiers in Psychiatry|May 24, 2021
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar DepressionOleksandr Sverdlov, Jelena Curcic, Kristin Hannesdottir, et al.
Pageof 1